Win-Partners Co

Win-Partners Co Capital Expenditures

The Capital Expenditures (CapEx) of Win-Partners Co (3183.T) as of Nov 4, 2026 is -227.05 M JPY. In the previous year, Capital Expenditures (CapEx) was -463.07 M JPY — a change of -50.97% (higher).

Capital Expenditures

-227.05 MJPY

YoY

-50.97%

Last updated:

Capital Expenditures (CapEx) of Win-Partners Co is 2026 -227.05 M JPY. Capital Expenditures (CapEx) of Win-Partners Co was 2025 -463.07 M JPY. It decreases by -50.97% higher compared to the previous year.

The Win-Partners Co Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2019
-91.42 M JPY
Jan 1, 2020
-107.86 M JPY
Jan 1, 2021
-1.18 B JPY
Jan 1, 2022
-2.76 B JPY
Jan 1, 2023
-970.31 M JPY
Jan 1, 2024
-502.58 M JPY
Jan 1, 2025
-463.07 M JPY
Jan 1, 2026
-227.05 M JPY
The Win-Partners Co Capital Expenditures history
YEARCapital ExpendituresYoY
-227.05 MJPY-50.97%
-463.07 MJPY-7.86%
-502.58 MJPY-48.20%
-970.31 MJPY-64.83%
-2.76 BJPY+134.48%
-1.18 BJPY+990.90%
-107.86 MJPY+17.97%
-91.42 MJPY-54.01%
-198.79 MJPY+57.15%
-126.50 MJPY-46.25%
-235.36 MJPY-53.58%
-507.00 MJPY-38.77%
-828.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Win-Partners Co Stock analysis

What does Win-Partners Co do? WIN-Partners Co., Ltd. generates revenue through the management of its group of companies specializing in medical device sales. The company offers catheters for ischemic heart disease, pacemakers for cardiac rhythm management, artificial blood vessels for cardiovascular surgery, and embolization coils for peripheral vascular disease and brain surgery. Additionally, it provides large-scale medical equipment including computed tomography (CT) systems for radiology departments and operating rooms. Its primary customers are healthcare institutions requiring advanced medical technology solutions. The company's product portfolio targets specific medical specialties, with catheters, pacemakers, and artificial blood vessels serving cardiovascular applications. Embolization coils address vascular and neurological procedures, while CT equipment supports diagnostic imaging needs across various hospital departments. These offerings are distributed through the company's managed group of medical device sales entities. WIN-Partners focuses on high-value medical devices that require specialized sales channels and technical support. Its business model centers on managing a network of companies that handle the distribution and sales of these medical technologies to hospitals and clinics. The firm's revenue streams are derived from the sale of these specialized medical devices and equipment to healthcare providers in Japan and potentially international markets. Win-Partners Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Win-Partners Co stock

Capital Expenditures (CapEx) of Win-Partners Co is -227.05 M JPY in 2026.

Capital Expenditures (CapEx) of Win-Partners Co changed from -463.07 M JPY to -227.05 M JPY, representing a -50.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Win-Partners Co since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Win-Partners Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Win-Partners Co

All Key Metrics — Win-Partners Co